Arcutis Biotherapeutics EVP, CLO Masaru Matsuda Sells $1.41M of Stock
Masaru Matsuda, EVP, CLO, sold 41,219 shares of Arcutis Biotherapeutics, Inc. at $31.86 to $34.32 a share (average $34.24) in 2 transactions, worth $1.41M in total between Nov 2, 2026 and Nov 4, 2026. Shares held after the trade: 111,289 (-26.4%).
Arcutis Biotherapeutics EVP, CMO Patrick Burnett Sells $30K of Stock
Patrick Burnett, EVP, CMO, sold 943 shares of Arcutis Biotherapeutics, Inc. at $31.86 a share, worth $30K in total on Nov 2, 2026. Shares held after the trade: 116,649 (-0.8%).
Arcutis Biotherapeutics Insider Todd Watanabe Sells $139K of Stock
Todd Watanabe sold 4,377 shares of Arcutis Biotherapeutics, Inc. at $31.86 a share, worth $139K in total on Nov 2, 2026. Shares held after the trade: 712,826 (-0.6%).
Arcutis Biotherapeutics reported a significant turnaround for the nine months ended September 30, 2026, achieving a net income of $12.5 million compared to a net loss of $33.5 million in the prior year period. This growth was driven by a 55% increase in net product revenue to $379.2 million, though operating expenses also rose to $362.4 million due to higher selling, general, and administrative costs.
Arcutis Biotherapeutics reported Q3 2026 net product revenues of $143.9 million, a 45% year-over-year increase driven by strong demand for its ZORYVE portfolio. The company maintained positive operating cash flow of $18.9 million and raised its full-year 2026 net product sales guidance to a range of $535 million to $545 million.
Term
quarter ended September 30, 2026
“Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position. ZORYVE continues to lead the branded non-steroidal topical segment driven by its efficacy and tolerability across multiple inflammatory skin conditions and patient populations.”
Frank Watanabe, president and chief executive officer
Arcutis Biotherapeutics appointed Dr. Robert Scott to its Board of Directors and the Nominating and Corporate Governance Committee, effective October 23, 2026. Dr. Scott, a former Chief Medical Officer at AbbVie and Amgen, joins as a Class II director with a term expiring in 2028. As part of his appointment, he received an initial stock option award for 20,507 shares of common stock.
Arcutis Biotherapeutics Insider Howard G. Welgus Sells $127K of Stock
Howard G. Welgus sold 4,728 shares of Arcutis Biotherapeutics, Inc. at $26.93 a share, worth $127K in total on Oct 15, 2026. Shares held after the trade: 35,207 (-11.8%).